Meng X, He J, Cheng F, Yan H, Zhu C, Guo X
Am J Case Rep. 2024; 25:e942534.
PMID: 38229422
PMC: 10806375.
DOI: 10.12659/AJCR.942534.
Hughes M, Lentzsch S
Ther Clin Risk Manag. 2024; 19:1063-1074.
PMID: 38164204
PMC: 10758190.
DOI: 10.2147/TCRM.S325859.
Zerdan M, George T, Bunting S, Chaulagain C
J Clin Med. 2022; 11(23).
PMID: 36498588
PMC: 9741379.
DOI: 10.3390/jcm11237011.
Ikura H, Endo J, Kitakata H, Moriyama H, Sano M, Fukuda K
Int J Mol Sci. 2022; 23(11).
PMID: 35683015
PMC: 9181426.
DOI: 10.3390/ijms23116336.
Sammartano V, Antonioli E, Buda G, Ciofini S, Candi V, Pengue L
J Pers Med. 2022; 12(3).
PMID: 35330483
PMC: 8952680.
DOI: 10.3390/jpm12030484.
Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis.
Stelmach-Goldys A, Zaborek-Lyczba M, Lyczba J, Garus B, Pasiarski M, Mertowska P
J Clin Med. 2022; 11(4).
PMID: 35207184
PMC: 8880759.
DOI: 10.3390/jcm11040911.
Nomogram Model for Dynamic and Individual Prediction of Cardiac Response and Survival for Light Chain Amyloidosis in 737 Patients With Cardiac Involvement.
Li Y, Cao Y, Zheng M, Hu J, Yan W, Liu X
Front Oncol. 2021; 11:758502.
PMID: 34956879
PMC: 8695981.
DOI: 10.3389/fonc.2021.758502.
T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab-based therapy.
Wang Y, Xu L, Zhao W, Chen X, Wen L, Duan W
Clin Transl Med. 2021; 11(11):e582.
PMID: 34845849
PMC: 8630449.
DOI: 10.1002/ctm2.582.
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: State-of-the-Art Review.
Bianchi G, Zhang Y, Comenzo R
JACC CardioOncol. 2021; 3(4):467-487.
PMID: 34729520
PMC: 8543128.
DOI: 10.1016/j.jaccao.2021.09.003.
Clinical trials evaluating potential therapies for light chain (AL) amyloidosis.
Muchtar E, Gertz M
Expert Opin Orphan Drugs. 2021; 5(8):655-663.
PMID: 34567849
PMC: 8460071.
DOI: 10.1080/21678707.2017.1341834.
Current Updates on the Management of AL Amyloidosis.
Elsayed M, Usher S, Habib M, Ahmed N, Ali J, Begemann M
J Hematol. 2021; 10(4):147-161.
PMID: 34527111
PMC: 8425803.
DOI: 10.14740/jh866.
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.
Sidiqi M, Gertz M
Blood Cancer J. 2021; 11(5):90.
PMID: 33993188
PMC: 8124067.
DOI: 10.1038/s41408-021-00483-7.
Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
Palladini G, Milani P, Malavasi F, Merlini G
Cells. 2021; 10(3).
PMID: 33806310
PMC: 7998921.
DOI: 10.3390/cells10030545.
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.
Castillo J, Libby E, Ansell S, Palomba M, Meid K, Flynn C
Blood Adv. 2020; 4(20):5089-5092.
PMID: 33085756
PMC: 7594378.
DOI: 10.1182/bloodadvances.2020003087.
Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience.
Roccatello D, Fenoglio R, Naretto C, Baldovino S, Sciascia S, Ferro M
J Clin Med. 2020; 9(10).
PMID: 33050272
PMC: 7600836.
DOI: 10.3390/jcm9103232.
Advances in the Treatment of Cardiac Amyloidosis.
Macedo A, Schwartzmann P, de Gusmao B, Melo M, Coelho-Filho O
Curr Treat Options Oncol. 2020; 21(5):36.
PMID: 32328845
PMC: 7181421.
DOI: 10.1007/s11864-020-00738-8.
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function.
Milani P, Basset M, Curci P, Foli A, Rizzi R, Nuvolone M
Blood Adv. 2020; 4(7):1321-1324.
PMID: 32251496
PMC: 7160273.
DOI: 10.1182/bloodadvances.2020001553.
Amyloid and the Heart.
Wolfson A, Shah K, Patel J
Curr Cardiol Rep. 2019; 21(12):164.
PMID: 31792619
DOI: 10.1007/s11886-019-1230-9.
New developments in diagnosis, risk assessment and management in systemic amyloidosis.
Vaxman I, Dispenzieri A, Muchtar E, Gertz M
Blood Rev. 2019; 40:100636.
PMID: 31706583
PMC: 7124973.
DOI: 10.1016/j.blre.2019.100636.
Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.
Sarosiek S, Sanchorawala V
J Blood Med. 2019; 10:373-380.
PMID: 31695543
PMC: 6815750.
DOI: 10.2147/JBM.S183857.
